Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label, Uncontrolled, Single-arm, Phase Ib/II Study of Intravenous Copanlisib in Japanese Patients With Indolent B-cell Non Hodgkin's Lymphomas Relapsed After or Refractory to Standard Therapy

NCT02342665 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT02342665
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02342665 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label, Uncontrolled, Single-arm, Phase Ib/II Study of Intravenous Copanlisib in Japanese Patients With Indolent B-cell Non Hodgkin's Lymphomas Relapsed After or Refractory to Standard Therapy
Lead sponsor
Bayer
Phase
Phase 1/2
Overall status
Completed
Start date
April 21, 2015
Completion date
February 10, 2022
Enrollment
25 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma non-hodgkin